Pre-Operative Prediction of Mediastinal Node Metastasis Using Radiomics Model Based on 18F-FDG PET/CT of the Primary Tumor in Non-Small Cell Lung Cancer Patients

Kai Zheng1,2,3, Xinrong Wang4, Chengzhi Jiang2, Yongxiang Tang1, Zhihui Fang1, Jiale Hou1, Zehua Zhu1 and Shuo Hu1,5,6*

1 Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, China, 2 Positron Emission Tomography/Computed Tomography (PET/CT) Center, Hunan Cancer Hospital, Changsha, China, 3 The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, 4 General Electric (GE) Healthcare (China), Shanghai, China, 5 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, 6 Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Changsha, China

Purpose: We investigated whether a fluorine-18-fluorodeoxy glucose positron emission tomography/computed tomography (18F-FDG PET/CT)-based radiomics model (RM) could predict the pathological mediastinal lymph node staging (pN staging) in patients with non-small cell lung cancer (NSCLC) undergoing surgery.

Methods: A total of 716 patients with a clinicopathological diagnosis of NSCLC were included in this retrospective study. The prediction model was developed in a training cohort that consisted of 501 patients. Radiomics features were extracted from the 18F-FDG PET/CT of the primary tumor. Support vector machine and extremely randomized trees were used to build the RM. Internal validation was assessed. An independent testing cohort contained the remaining 215 patients. The performances of the RM and clinical node staging (cN staging) in predicting pN staging (pN0 vs. pN1 and N2) were compared for each cohort. The area under the curve (AUC) of the receiver operating characteristic curve was applied to assess the model’s performance.

Results: The AUC of the RM [0.81 (95% CI, 0.771–0.848); sensitivity: 0.794; specificity: 0.704] for the predictive performance of pN1 and N2 was significantly better than that of cN [0.685 (95% CI, 0.644–0.728); sensitivity: 0.804; specificity: 0.568], (P-value = 8.29e-07, as assessed by the Delong test). In the testing cohort, the AUC of the RM [0.766 (95% CI, 0.702–0.830); sensitivity: 0.688; specificity: 0.704] was also significantly higher than that of cN [0.685 (95% CI, 0.619–0.747); sensitivity: 0.799; specificity: 0.568], (P = 0.0371, Delong test).

Conclusions: The RM based on 18F-FDG PET/CT has a potential for the pN staging in patients with NSCLC, suggesting that therapeutic planning could be tailored according to the predictions.

Keywords: non-small cell lung cancer, 18F-FDG PET/CT, radiomics analysis, lymph node staging, predict, primary tumor
INTRODUCTION

Among all cancers, lung cancer remains the most commonly diagnosed (11.6% of the total cases) and leading cause of cancer death (18.4% of the total cancer deaths). Non-small cell lung cancer (NSCLC) accounts for 85% of the cases (1, 2). For patients newly diagnosed with NSCLC, the exact evaluation of the pathological lymph node (LN) status plays an important role in the choice of therapy regimen. There is a consensus that lobectomy combined with systemic nodal dissection is the recommended surgical treatment for early-stage NSCLC; however, sublobar resection and stereotactic body radiation therapy (SBRT) are possible alternatives for patients who are ineligible for lobectomy (3–5). Thus, accurate differentiation of pathological node-negative from positive is critical for selecting the optimal therapeutic plan.

Currently, one of the most widespread modalities used for the clinical LN (cN) staging of patients with NSCLC is fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) (6, 7). Unfortunately, the accuracy of 18F-FDG PET for the direct evaluation of each mediastinal LN for the presence of metastasis is inherently limited by an avid FDG uptake that can be caused by inflammation due to infectious or non-infectious etiologies such as tuberculosis, pneumoconiosis, or chronic obstructive pulmonary disease (8–10). To improve the diagnostic ability of false-positive signs, several studies have analyzed the differences in parameters such as morphology, density, metabolism, and radiomics between benign and malignant LNs (11, 12). Nevertheless, because of the low FDG uptake, occult LN metastasis (OLM) in patients with NSCLC fails to be detected by 18F-FDG PET (13) and, hence, imaging is prone to false-negative signs. Accordingly, some researchers have tried to predict OLM by analyzing the 18F-FDG metabolic parameters of the primary tumor in NSCLC (14, 15). To the best of our knowledge, few researchers have dealt with both problems of false-positive signs and OLM in mediastinal LN staging. Furthermore, few studies have investigated whether radiomics features derived from the primary lesion of NSCLC might provide useful information for mediastinal LN staging.

Therefore, we constructed and validated a radiomics model (RM) to predict the pathological mediastinal LN staging (pN0 vs. pN1 and pN2) based on the 18F-FDG PET/CT imaging of NSCLC primary tumors.

MATERIALS AND METHODS

Patients

This study involving human participants was reviewed and approved by the Ethical Commission of Medical Research Involving Human Subjects at the Region of Xiangya Hospital, Central South University, China, and the requirement for informed consent was waived. We reviewed the electronic medical records of 716 consecutive patients with NSCLC [adenocarcinoma (ADC) and squamous cell carcinoma (SCC)] who underwent both 18F-FDG PET/CT staging and surgical resection with a curative intent from February 2007 to November 2019. All the patients underwent surgical resection with systematic mediastinal (N2) and hilar (N1) LN dissections within 2 weeks of 18F-FDG PET/CT examination. Pre-operative cN staging and post-operative pN staging of the patients were performed and recorded according to the eighth edition of the Union for International Cancer Control TNM classification (16). Histological types were diagnosed according to the World Health Organization classification. We excluded patients from the study if they had (i) pathology other than ADC or SCC, (ii) history of other cancer, (iii) received any treatment before 18F-FDG PET/CT, and (iv) undergone pre-operative lung biopsy.

18F-FDG PET/CT Acquisition and Reconstruction

All 18F-FDG PET/CT scans were performed on a dedicated PET/CT scanner (Discovery ST8, GE Healthcare, Chicago, IL). All patients fasted for at least 6 h before imaging, and a blood glucose level of <110 mg/dL was confirmed before the administration of 18F-FDG. PET/CT was performed ~60 min after the intravenous injection of 370 MBq/kg of 18F-FDG. First, a low-dose CT scan without contrast enhancement (120 mA, 150 kV, 512 × 512 matrix, the pitch of 1.75, reconstruction thickness and interval of 3.75 mm) for a precise anatomical localization and attenuation correction was performed. Next, a three-dimensional PET scan (thickness of 3.27 mm) was performed from the skull base to the proximal thighs with an acquisition time of 3 min per bed position.

The PET data sets were iteratively reconstructed using an ordered-subset expectation maximization (OSEM) algorithm with attenuation correction. All collected images were displayed on the GE Healthcare Xeleris 3.0 to reconstruct the PET, CT, and PET/CT fusion images.

Image Interpretation and Lesion Segment

Two experienced nuclear medicine physicians who were blinded to the patient’s clinical information retrospectively reviewed the 18F-FDG PET/CT scans. Any difference of opinion was resolved by consensus. Mediastinal and hilar LNs with a short axis of ≥10 mm in the short axis on CT and with a high accumulation of 18F-FDG compared with that of the adjacent mediastinal tissue were considered as cN2 or cN1 at our institution. Fused PET/CT images were viewed on the Advantage Workstation (version AW 4.7, GE Healthcare).

The region of interest (ROI) for each patient was delineated initially around the tumor outline for the largest cross-sectional area of the primary lung lesion on both the CT and PET images. The ROIs were segmented manually by a single experienced nuclear medicine physician, and the final ROIs were checked by another nuclear medicine physician with more than 10 years of experience in PET/CT diagnosis. The open-source imaging platform ITK-SNAP software (version 3.6; www.itksnap.org) was used to plot the ROIs of the corresponding lesions (17). The feature data were extracted, pre-processed, modeled, evaluated, and validated using the scikit-learn (sklearn, scikit-learn.org) packages in the python platform (18).
Radiomics Feature Extraction
Data pre-processing: to ensure that the features were comparable, training/testing cohort division, missing-value filling, and data standardization were performed. First, to maintain the distribution of the original data, a stratified sampling method was applied to identify the training (501 samples, 70%) and testing cohorts (215 samples, 30%) (19). Moreover, the missing values (0 and 5) were filled with the median in the training and testing cohorts, respectively, and then, the same normalization was used for the data.

There were 1,438 features of primary tumors that were automatically extracted using the sklearn packages. The Spearman rank order correlation coefficient was used to calculate the relationship between features, and the redundant features were eliminated with an average absolute correlation of 0.85 as the threshold. Support vector machine–recursive feature elimination, and the extremely randomized trees were applied to reduce the dimensions and select optimized features for the radiomics model (RM) to avoid the impact of redundant and unconnected features. The relevance of the association between each radiomics feature was established using heat maps (Figure 1). Consequently, a total of 25 principal correlative features, obtained through dimension reduction, were identified for inclusion in the RM to distinguish pN0 from pN1 and pN2. The results of the feature selection are shown in Table 1.

Radiomics Modeling and Evaluation
Extremely randomized trees was used as a classifier to model and optimize the radiomics signature in the modeling process. The 25 selected features were put into the classifier to build the RM to predict the pathological status of mediastinal LNs in the training cohort. Thereafter, a five-fold cross-validation of the training cohort was used to identify differences in the results. The training model was applied to the testing cohort for model validation. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve was used as a means of quantitatively identifying the effective performance of the RM. The confusion matrix in the testing cohort was calculated (Figure 2).

Statistical Analysis
Statistical analyses were conducted using the SPSS software, version 23.0 (IBM Corp., Armonk, NY), and $P$-values $< 0.05$ were deemed statistically significant.

The predictive abilities of the RM and cN were investigated using ROC analysis. The statistical significance of the improvement in the AUC after adding an explanatory factor was evaluated using the Delong test (20).

The clinicopathologic characteristics of the patients with a pN0 status were compared with those of the patients with pN1 and pN2. The training and testing data cohorts were compared to identify factors contributing to nodal metastasis

FIGURE 1 | Heat map showing the correlation of radiomics features in the training cohort. The intensity of the relevance of each feature is displayed as a certain color. The darker the color, the higher the relevance, and the lighter the color, the lower the relevance.
TABLE 1 | The list of selected radiomics features.

| Characteristic type                        | Description                                                                 | Selected features                                                                 |
|--------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Histogram feature                          | Histogram parameters are related to the properties of individual pixels. They describe the distribution of voxel intensities within the images through the commonly used and basic metrics. Let X denote the 3D image matrix with voxels and the first-order histogram divided by discrete intensity levels. | PET_original_firstorder_Minimum                                                   |
| Textural phenotype features                 | Texture is one of the important characteristics used in identifying objects or regions of interest in an image. Texture represents the appearance of the surface and how its elements are distributed. It is considered an important concept in machine vision; in a sense, it assists in predicting the feeling of the surface (e.g., smoothness, coarseness, etc.) from image. | PET_textural_phenotype_level_H                                                   |
| Intra-peri-nodular textural transition features | Intra-peri-nodular textural transition features represents a minimal set of quantitative measurements which attempt to capture the transitional heterogeneity from the intrato the peri-nodular space. | PET_Ipris_shell0_ge_mean                                                          |
| Partial local pattern binary feature        | Partial local pattern binary feature is a local descriptor of the image based on the neighborhood for any given pixel. The neighborhood of a pixel is given in the form of \( P \) number of neighbors within a radius of \( R \). | PET_PLBP_hist_tumor_orient6_0, CT_PLBP_hist_tumor_orient2_7, CT_PLBP_hist_tumor_orient2_3, PET_PLBP_hist_tumor_orient3_1, PET_PLBP_hist_tumor_orient4_3, CT_PLBP_hist_tumor_orient1_2 |
| High order texture feature based on wavelet transform | By using a family of functions localized in terms of time and frequency, wavelet transforms can centralize the energy of the original image within only a few coefficients after wavelet decomposition. These coefficients have high local relativity in three directions of different sub-band images: horizontal, vertical, and diagonal. | CT_wavelet-LHL_lbp-3D-m2_firstorder_90Percentile, CT_wavelet-LLL_lbp-3D-m2_firstorder_InterquartileRange, PET_wavelet-HLL_lbp-3D-m2_firstorder_Median, PET_wavelet-HHL_lbp-3D-m1_firstorder_Skewness, CT_wavelet-LH_lbp-3D-m1_firstorder_Median, PET_wavelet-LHL_lbp-3D-m1_firstorder_Median, CT_wavelet-HLL_lbp-3D-m1_firstorder_90Percentile, CT_WL_lbp_hist_cH1_1, PET_WL_lbp_hist_cD1_4, PET_wavelet-HLL_lbp-3D-m1_firstorder_Median, CT_wavelet-HLL_lbp-3D-m2_firstorder_Range, PET_wavelet-HHL_lbp-3D-k_firstorder_Minimum, PET_WL_lbp_hist_cH2_2, CT_wavelet-LLL_lbp-3D-m1_firstorder_Median, CT_WL_lbp_hist_cV2_7 |

using the \( \chi^2 \)-test for categorical data and the one-sample \( t \)-test for continuous variables.

RESULTS
Characteristics of All Patients
The clinicopathological characteristics of the 716 patients enrolled in the study are shown in Table 2. Figure 3 shows the patient recruitment pathway. Among them, 220 were female and 496 were male, with an age range from 25 to 78 years. ADC was the most common histological type of NSCLC (417/716). The number of patients with SCC was 329. In the training cohort, the number of patients with pN0, pN1, and pN2 were 315, 74, and 112, respectively. In the testing cohort, the number of patients with pN0, pN1, and pN2 were 135, 43, and 37, respectively. The age of the training cohort, sex of the testing cohort, and
FIGURE 2 | Confusion matrix of the radiomics model in the testing cohort. The abscissas and ordinates represent the true and predictive labels, respectively.

TABLE 2 | Clinical characteristics.

| Characteristic         | Training cohort | P       | Testing cohort | P       |
|------------------------|-----------------|---------|----------------|---------|
|                        | pN0 (n = 315)   | pN1&2 (n = 186) |         | pN0 (n = 135) | pN1&2 (n = 80) |
| Age, mean ± SD, years  | 60 ± 9          | 58 ± 9  | 0.005\(^a\)  | 60 ± 9   | 58 ± 9  | 0.152\(^a\) |
| Gender, No. (%)        |                 | 0.627   | 0.041         |         |         |         |
| Male                   | 212             | 128     | 0.005\(^a\)  | 90       | 66      | 0.005\(^a\) |
| Female                 | 103             | 58      | 0.152\(^a\)  | 45       | 14      | 0.152\(^a\) |
| Smoking history        |                 | 0.810   | 0.206         |         |         |         |
| Yes                    | 181             | 108     | 0.214         | 78       | 52      | 0.385 |
| No                     | 134             | 78      | 0.385         | 57       | 28      | 0.385 |
| Lobar distribution     |                 | 0.214   | 0.385         |         |         |         |
| LUL                    | 77              | 45      | 0.214         | 40       | 25      | 0.214 |
| LLL                    | 46              | 28      | 0.214         | 25       | 15      | 0.214 |
| RUL                    | 57              | 52      | 0.214         | 17       | 21      | 0.214 |
| RML                    | 28              | 13      | 0.214         | 11       | 1      | 0.214 |
| RLL                    | 107             | 48      | 0.214         | 42       | 18      | 0.214 |
| Anatomical classification |                 | 0.02    | 0.008         |         |         |         |
| Central lung cancer    | 53              | 52      | 0.02          | 25       | 27      | 0.008 |
| Peripheral lung cancer | 263             | 133     | 0.02          | 25       | 27      | 0.008 |
| Histologic cell type   |                 | 0.696   | 0.697         |         |         |         |
| SCC                    | 109             | 67      | 0.696         | 52       | 38      | 0.696 |
| ADC                    | 207             | 119     | 0.696         | 83       | 42      | 0.696 |

RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.

RM Performance

The diagnostic efficiency of the RM and cN were evaluated by the ROC curve. The AUC of the RM [0.81 (95% CI, 0.771–0.848); sensitivity: 0.794; specificity: 0.704] for the predictive performance of the pathological node status was significantly better than that of the cN in the training cohort [0.685 (95% CI, 0.644–0.728); sensitivity: 0.804;
specificity: 0.568], (P = 8.29e-07, as assessed using the Delong test).

In the testing cohort, the AUC of the RM [0.766 (95% CI, 0.702–0.830); sensitivity: 0.688; specificity: 0.704] was also significantly higher than that of the cN [0.685 (95% CI, 0.619–0.747); sensitivity: 0.799; specificity: 0.568], (P = 0.0371, as assessed using the Delong test).

The above-mentioned nuclear medicine physicians excluded the patients with LNs significant enlargement and intense 18F-FDG uptake in PET/CT, and confirmed N1 or N2 by pathology from the whole population. The remaining 634 patients were defined as the cN ± group. Then, the sensitivity, specificity, and AUC of the cN and the RM in the cN ± group were calculated, respectively.

The RM showed the AUC of 0.802 (95%CI, 0.683–0.921) for the prediction of mediastinal LNs malignancy using the optimum cutoff value of 0.382 in the cN ± group. The sensitivity and specificity of the RM were 0.718 and 0.767, respectively. In comparison, the cN showed the AUC of 0.611 (95% CI, 0.572–0.650) using the optimum cutoff value of 0.500. The sensitivity and specificity of the cN were 0.819 and 0.404, respectively. The results demonstrated that the performance of the RM was effective in discriminating pN0 from pN1 and pN2 using the 18F-FDG PET/CT images. The performances of the RM and cN in the training and testing cohorts and the cN ± group are displayed in detail in Figures 3, 4 and 5, respectively, and the representative cases are presented in Figure 6.

DISCUSSION

In cases of NSCLC with a chance of cure, the standard surgical procedure is a pulmonary lobectomy with systemic mediastinal nodal dissection. However, some patients are not eligible for this therapy because of their advanced age or the presence of severe medical diseases, and some patients refuse surgical treatment. Limited surgery (wedge resection or segmentectomy) or SBRT would be alternatives for such patients. Sublobar resection helps preserve more healthy lung tissue, shortens the operative time, and improves the post-operative quality of life. Perioperative mortality and operative complication morbidity do not differ significantly between lobar and sublobar resection (3). SBRT has emerged as the preferred management strategy for patients who are not surgical candidates; however, for the selection of SBRT or restrictive surgery, accurate prediction of a pathological LN-negative status is a pre-requisite.

The diagnosis of NSCLC mediastinal LN metastasis is generally based on several parameters such as metabolism, size, morphology, and attenuation, which leads to dependence on clinical experience. In other words, the traditional practice involves treating medical images as pictures intended solely for visual interpretation (21). False-positive findings of mediastinal LNs are not uncommon in functional imaging with 18F-FDG PET/CT because the modality can mistakenly identify inflammation in patients with NSCLC due to infection, inflammation, or granulomatous diseases (8–10). The main molecular and pathological mechanisms of an avid FDG uptake in benign mediastinal LNs are lymphoid follicular hyperplasia and histioyte infiltration associated with glucose transporter-1 overexpression (22). When benign mediastinal LNs manifest as a false-positive finding on PET imaging, and the CT morphology is not informative enough to support a judgment, there is an increased risk of an incorrect diagnosis. Benign high-uptake LNs can coexist with occult metastasis, making an accurate cN staging more difficult. In the clinical practice of mediastinal LN staging in NSCLC, nuclear medicine physicians are faced with the challenge of suspected positive LNs and possible OLM almost every day, which is difficult to deal with by relying solely on experience.

In the existing studies, for the accuracy of the cN staging in NSCLC, radiologists and nuclear physicians often analyzed parameters such as morphology and glucose metabolism or radiomic features of visible mediastinal LNs to improve the diagnostic ability of 18F-FDG PET/CT for metastasis (23–25). Gao et al. researched the method and efficacy of support vector machine classifiers based on texture features and a multi-resolution histogram to evaluate mediastinal LNs (11). Flechsig et al. used density as a threshold for the detection of malignant LN infiltration in a radiomics analysis of patients with NSCLC (12). Likewise, Lee et al.’s research indicated that the risk of mediastinal LN metastasis in NSCLC patients could be further stratified using both 18F-FDG uptake and LN density (24). Cho et al. attempted to determine the optimal cut-off values of the mediastinal LN standardized uptake values (SUV-LN)/primary tumor SUV (SUV-T) ratio to discriminate metastatic LNs from benign LNs (26). However, these researchers faced the common problem of an unpredictable OLM. Some algorithms for the
analysis of parameters based on $^{18}$F-FDG uptake have been proposed in light of these limitations. Ouyang et al. used the primary tumor-to-blood SUV ratio and metabolic parameters in clinical N0 lung ADC to predict OLM (14). Kim et al. investigated the OLM’s predictability using SUV, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) in patients with cN0 lung SCC before surgery (15). There are no current studies of $^{18}$F-FDG PET/CT primary tumor-based
Nevertheless, the present study has several limitations too. Due to its retrospective design and performance at a single center, there is a risk of selection bias. A larger, multi-institutional prospective randomized study is needed to confirm these results.

**CONCLUSIONS**

A Radiomics Model based on the 18F-FDG PET/CT analysis provided useful information for mediastinal LN staging in patients with NSCLC. Therefore, therapeutic planning could be tailored according to predictions, and limited surgery or SBRT could be helpful in patients with cN0.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Ethical Commission of Medical Research Involving Human Subjects at Region of Xiangya Hospital, Central South University, China. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

KZ designed the method, acquired the data, and wrote and edited the article. SH designed the method and approved the manuscript. Image analysis was performed by XW. Statistical analysis was performed by XW and CJ. YT, ZF, JH, and ZZ aided in data acquisition and interpretation. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by the National Natural Science Foundation of China (Nos. 91859207, 81771873, and 81471689).

**ACKNOWLEDGMENTS**

We thank the patients who were included in this research project and the staff who developed the ITK-SNAP and sklearn package.

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Erratum: global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2020) 70:313. doi: 10.3322/caac.21609
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. (2016) 66:115–32. doi: 10.3322/caac.21338
3. Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, et al. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). 
Lancet Respir Med. (2018) 6:915–24. doi: 10.1016/S2213-2600(18)30411-9

4. Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. 
Lancet Oncol. (2019) 20:494–503. doi: 10.1016/S1470-2045(18)30896-9

5. Phillips I, Sandhu S, Luchtenborg M, Harden S. Stereotactic ablative body radiotherapy versus radical radiotherapy: comparing real-world outcomes in stage I lung cancer. 
Clin Oncol (R Coll Radiol). (2019) 31:681–7. doi: 10.1016/j.clon.2019.07.013

6. Abramyuk A, Appold S, Zophel K, Hietchold V, Baumann M, Abolmaali N. Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy—a retrospective study. 
Lung Cancer. (2012) 78:148–52. doi: 10.1016/j.lungcan.2012.08.001

7. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. 
Radiology. (2004) 231:305–32. doi: 10.1148/radiol.23120121185

8. Kang F, Wang S, Tian F, Zhao M, Zhang M, Wang Z, et al. Comparing the diagnostic potential of 68Ga-alatide II and 18F-FDG in differentiating between non-small cell lung cancer and tuberculosis. 
J Nucl Med. (2016) 57:672–7. doi: 10.2967/jnumed.115.167924

9. Choi EK, Park HL, Yoo IR, Kim SJ, Kim YK. The clinical value of F-18 FDG PET/CT in differentiating malignant from benign lesions in pneumococci patients. 
Eur Radiol. (2020) 30:442–51. doi: 10.1007/s00330-019-06342-1

10. Fleischg P, Kratochwil C, Schwartz LH, Rath D, Moltz J, Antoch G, et al. Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer. 
J Nucl Med. (2014) 55:599–64. doi: 10.2967/jnumed.113.128504

11. Gao X, Chu C, Li Y, Lu P, Wang W, Liu W, et al. The method and efficacy of support vector machine classifiers based on texture features and multi-resolution histogram from (18)F-FDG PET-CT images for the evaluation of mediastinal lymph nodes in patients with lung cancer. 
Eur J Radiol. (2015) 84:312–7. doi: 10.1016/j.ejrad.2014.11.006

12. Fleischg P, Frank P, Kratochwil C, Antoch G, Rath D, Moltz J, et al. Radiomic analysis using density threshold for FDG-PET/CT-based N-staging in lung cancer patients. 
Mol Imaging Biol. (2017) 19:315–22. doi: 10.1007/s11307-016-0996-z

13. Farjah F, Lou F, Sima C, Frank P, Kratochwil C, Rath D, Moltz J, et al. Correlation between SUVmax and CT radiomic analysis using lymph node density in PET/CT-based lymph node staging. 
J Nucl Med. (2017) 58:282–7. doi: 10.2967/jnumed.116.179648

14. Lee JW, Kim EY, Kim DI, Lee JH, Kang WJ, Lee JD, et al. The diagnostic ability of (18)F-FDG PET/CT for mediastinal lymph node staging using (18)F-FDG uptake and volumetric CT histogram analysis in non-small cell lung cancer. 
Eur Radiol. (2016) 26:4515–23. doi: 10.1007/s00330-016-2492-8

15. Yin G, Song Y, Li X, Zhu L, Su Q, Dai D, et al. Prediction of mediastinal lymph node metastasis based on (18)F-FDG PET/CT imaging using support vector machine in non-small cell lung cancer. 
Eur Radiol. (2020) 31:3983–92. doi: 10.1007/s00330-020-07466-3

16. Cho J, Choe JG, Park K, Choi S, Kwon HR, Eo JS, et al. Ratio of mediastinal lymph node SUV to primary tumor SUV in (18)F-FDG PET/CT for nodal staging in non-small cell lung cancer. 
Nucl Med Mol Imaging. (2017) 51:140–6. doi: 10.1016/j.snm.2016.04.047-4

17. Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, et al. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. 
J Clin Oncol. (2016) 34:2157–64. doi: 10.1200/JCO.2015.65.9128

18. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. 
Nature. (2010) 467:1109–13. doi: 10.1038/nature09460

19. Arshad MA, Thornton A, Lu H, Tam H, Wallitt K, Rodgers N, et al. Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. 
Eur J Nucl Med Mol Imaging. (2018) 45:207–17. doi: 10.1007/s00259-016-3837-7

20. Kirienko M, Cozzi L, Antonovic L, Lozza L, Fogliata A, Voulaz E, et al. Detection of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery. 
Eur J Nucl Med Imaging. (2018) 45:207–17. doi: 10.1007/s00259-017-3837-7

21. Dong X, Sun X, Sun L, Maxim PG, Xing L, Huang Y, et al. Early change in metabolic tumor heterogeneity during chemoradiotherapy and its prognostic value for patients with locally advanced non-small cell lung cancer. 
PLoS ONE. (2016) e0157836. doi: 10.1371/journal.pone.0157836

22. Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z, et al. Radiomics signature: a potential biomarker for the prediction of disease-free survival in early-stage (I or II) non-small cell lung cancer. 
Radiology. (2016) 281:947–57. doi: 10.1148/radiol.2016152234

Conflict of Interest: XW was employed by the company GE healthcare (China).

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zheng, Wang, Jiang, Tang, Fang, Hou, Zhu and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.